NEW YORK (GenomeWeb News) – The New York Genome Center, a planned center focused on sequencing and bioinformatics to be based in New York City, this week named its board of directors. Nancy Kelley, a life sciences development executive and attorney, is the center's founding executive director. Russel Carson, a general partner at Welsh, Carson, Anderson and Stowe, is the chairman of NYGC's board.
NYGC's other board members include Herbert Pardres, vice chairman of the board of trustees at New York Presbyterian Hospital; Bruce Stillman, president of Cold Spring Harbor Laboratory; Lee Goldman, executive VP for health and dean of the Faculties of Health Sciences and Medicine at Columbia University; Antonio Gotto, dean of Weill Cornell Medical College, Cornell University; Charles Hewett, executive VP and COO at the Jackson Laboratory; Craig Thompson, president of Memorial Sloan Kettering Cancer Center; Dennis Charney, Dean of Mount Sinai School of Medicine; Dafna Bar-Sagi, senior VP and vice dean for science and CSO of New York University/NYU School of Medicine; Marc Tessier-Lavigne, president of The Rockefeller University; James Simons, founder of the Simons Foundation; Samuel Stanley, president of Stony Brook University; and Anthony Evnin, a partner at Vernrock.
Illumina said this week that it has appointed Daniel Grosu as Chief Medical Officer, a newly created position at the company. Grosu will play a key role in building Illumina’s diagnostic capabilities through collaborations with regulatory agencies, internal product development teams, and Illumina’s CLIA-certified clinical laboratory, the company said. Prior to joining Illumina, Grosu was group director of clinical science and clinical and medical affairs at Ortho-Clinical Diagnostics. He also was previously the director and leader of global clinical development and diagnostic imaging at Bayer Healthcare Pharmaceuticals. Grosu also has worked for Siemens Medical Solutions.
Ohio State University Assistant Professor of Clinical Internal Medicine Amy Sturm has received the Outstanding Volunteer Award from the National Society of Genetic Counselors. Sturm received the award for her work with various committees, task forces, and projects seeking to advance the role of genetic counselors in health care.
Pathwork Diagnostics has hired Sharon Tetlow to be its new CFO. Tetlow recently was VP and CFO of Cell Genesys and she was a venture partner at Apax Partners.
Janet Allen has resigned her post as director of research at the Biotechnology and Biological Sciences Research Council. Allen held the role for three years, during which time she worked in planning BBSRC's programs in basic bioscience for health, bioenergy, and global food security.
Medical diagnostics company Miraculins said this week that Albert Friesen has resigned from its board of directors to pursue other corporate interests.
Sialix has appointed Norrie Russell to be its new president and CEO. Russel most recently was president of Gene Logic and formerly was president and COO of NovaRx and general manager of Invitrogen's Functional Genomics business and its CSO.
Bio-Rad Laboratories has appointed Deborah Neff to its board of directors, and she will stand for election at a company stockholder meeting, the company said this week in a filing with the US Securities and Exchange Commission.
Saladax Biomedical this week said it has appointed Edward Chu to be chair of its scientific advisory board. Chu is chief of the division of hematology/oncology in the Department of Medicine at the University of Pittsburgh School of Medicine and deputy director of the University of Pittsburgh Cancer Institute.
Oxford Gene Technology has appointed Tim Hall to be its new finance director, a position he will assume in the beginning of 2012. Hall previously was director of strategic planning at Medeva, CFO at Celltech Pharmaceuticals, and finance director of Lombardi Medical Technologies.
H3 Biomedicine has tapped Markus Warmuth to be its CEO, effective immediately. Warmuth started at the company in August as CSO, and before that he was head of Oncology Drug Discovery at the Novartis Institute for Biomedical Research. He also formerly was director of kinase biology at the Genomics Institute of the Novartis Research Foundation.
The Genetics Society of American has appointed Adam Fagen to be its executive director, effective Dec. 1. He currently is director of public affairs at the American Society of Plant Biologists. Phyllis Edelman will continue to serve as GSA's executive director until he arrives.
23andMe has named Ruben Mesa to serve on its Myeloproliferative Neoplasms research project advisory board. Mesa has been a professor at Mayo Clinic since 2002, where he currently is chair of the Division of Hematology and Medical Oncology.